Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma

作     者：Jia-Ni Wang Quan-Hui Qiao Xing-Sheng Hu Yu-Tao Liu Zhi-Jie Wang Jian-Chun Duan Yu Feng Hao-Hua Zhu Wang Jia-Ni;Qiao Quan-Hui;Hu Xing-Sheng;Liu Yu-Tao;Wang Zhi-Jie;Duan Jian-Chun;Feng Yu;Zhu Hao-Hua

作者机构：Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical OncologyGongyi People’s HospitalGongyiHenan 451200China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2021年第134卷第17期

页      面：2119-2121页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：chemotherapy pemetrexed adenocarcinoma 

摘      要：To the Editor:Pemetrexed plus platinum(cisplatin or carboplatin)chemotherapy doublets are widely recommended as the standard first-line treatment for non-small cell lung cancer(NSCLC)with no identified genetic mutations.[1]However,their efficiency has been confirmed with a median survival of approximately 10.2 to 13.0 months and a 5-year survival rate of 13%to 15%.Initial chemotherapy with pemetrexed has been confirmed as an effective regimen for advanced lung adenocarcinoma without specific genetic biomarker predicting the benefit of pemetrexed efficacy.[2]Patients treated with pemetrexedbased regimens can also receive a single agent as maintenance treatment after the induction chemotherapy.